BACKGROUND: Preeclampsia (PE), a human pregnancy-specific disorder is characterized by an anti-angiogenic state due to high levels of circulating soluble vascular endothelial growth factor 1 (sVEGFR-1). However, the role of lymphangiogenesis in PE has not been investigated. Recently, impaired vascular endothelial growth factor C (VEGF-C) (factor that regulates lymphangiogenesis) signaling has been implicated in the pathogenesis of interstitial edema and salt-sensitive hypertension. Therefore, we hypothesized that circulating VEGF-C and its circulating receptors (sVEGFR-2 and sVEGFR-3) may also be altered in PE and correlate with the severity of the phenotype. METHODS: We analyzed plasma levels of VEGF-C, sVEGFR-1, sVEGFR-2, and sVEGFR-3 in women with gestational hypertension (GHTN, n = 20), PE (n = 20), and normotensive pregnancies (NP, n = 20) in the third trimester and values were reported as mean ± SD in pg/mL. RESULTS: As previously reported, sVEGFR-1 levels were significantly higher in subjects with PE (19,938 ± 12,973) than in GHTN (7156 ± 5432), p < 0.01 or NP (7760 ± 6018), p < 0.01. VEGF-C levels were lower in subjects with GHTN (676 ± 323) than in PE (1335 ± 625), p < 0.01, but not statistically different than in NP (971 ± 556), p = 0.11. There was a trend toward lower sVEGFR-2 in PE as compared to GHTN or NP. Interestingly, sVEGFR-3 was significantly lower in PE (54,371 ± 21,107) as compared to NP (83,709 ± 24,983), p < 0.01, but not different as compared to GHTN (54,642 ± 26,947). The ratio of sVEGFR-2 + sVEGFR-3/VEGF-C was dramatically lower during PE (57 ± 38) as compared to GHTN (113 ± 72), p < 0.01 or NP (133 ± 91), p < 0.01. CONCLUSIONS: PE is characterized by circulating pro-lymphangiogenic state as evidenced by decreased sVEGFR-3, slightly decreased sVEGFR-2, increased VEGF-C, and a dramatically lower ratio of sVEGFR-2 + sVEGFR-3/VEGF-C. Our data suggest that the circulating pro-lymphangiogenic state during PE may be a compensatory response to edema and hypertension. Additional studies are needed to evaluate the clinical relevance of the altered lymphangiogenic signaling pathway during PE.
BACKGROUND: Preeclampsia (PE), a human pregnancy-specific disorder is characterized by an anti-angiogenic state due to high levels of circulating soluble vascular endothelial growth factor 1 (sVEGFR-1). However, the role of lymphangiogenesis in PE has not been investigated. Recently, impaired vascular endothelial growth factor C (VEGF-C) (factor that regulates lymphangiogenesis) signaling has been implicated in the pathogenesis of interstitial edema and salt-sensitive hypertension. Therefore, we hypothesized that circulating VEGF-C and its circulating receptors (sVEGFR-2 and sVEGFR-3) may also be altered in PE and correlate with the severity of the phenotype. METHODS: We analyzed plasma levels of VEGF-C, sVEGFR-1, sVEGFR-2, and sVEGFR-3 in women with gestational hypertension (GHTN, n = 20), PE (n = 20), and normotensive pregnancies (NP, n = 20) in the third trimester and values were reported as mean ± SD in pg/mL. RESULTS: As previously reported, sVEGFR-1 levels were significantly higher in subjects with PE (19,938 ± 12,973) than in GHTN (7156 ± 5432), p < 0.01 or NP (7760 ± 6018), p < 0.01. VEGF-C levels were lower in subjects with GHTN (676 ± 323) than in PE (1335 ± 625), p < 0.01, but not statistically different than in NP (971 ± 556), p = 0.11. There was a trend toward lower sVEGFR-2 in PE as compared to GHTN or NP. Interestingly, sVEGFR-3 was significantly lower in PE (54,371 ± 21,107) as compared to NP (83,709 ± 24,983), p < 0.01, but not different as compared to GHTN (54,642 ± 26,947). The ratio of sVEGFR-2 + sVEGFR-3/VEGF-C was dramatically lower during PE (57 ± 38) as compared to GHTN (113 ± 72), p < 0.01 or NP (133 ± 91), p < 0.01. CONCLUSIONS: PE is characterized by circulating pro-lymphangiogenic state as evidenced by decreased sVEGFR-3, slightly decreased sVEGFR-2, increased VEGF-C, and a dramatically lower ratio of sVEGFR-2 + sVEGFR-3/VEGF-C. Our data suggest that the circulating pro-lymphangiogenic state during PE may be a compensatory response to edema and hypertension. Additional studies are needed to evaluate the clinical relevance of the altered lymphangiogenic signaling pathway during PE.
Authors: S Ananth Karumanchi; Sharon E Maynard; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme Journal: Kidney Int Date: 2005-06 Impact factor: 10.612
Authors: Yan Zhou; Michael McMaster; Kirstin Woo; Mary Janatpour; Jean Perry; Terhi Karpanen; Kari Alitalo; Caroline Damsky; Susan J Fisher Journal: Am J Pathol Date: 2002-04 Impact factor: 4.307
Authors: Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808
Authors: Agnes Machnik; Wolfgang Neuhofer; Jonathan Jantsch; Anke Dahlmann; Tuomas Tammela; Katharina Machura; Joon-Keun Park; Franz-Xaver Beck; Dominik N Müller; Wolfgang Derer; Jennifer Goss; Agata Ziomber; Peter Dietsch; Hubertus Wagner; Nico van Rooijen; Armin Kurtz; Karl F Hilgers; Kari Alitalo; Kai-Uwe Eckardt; Friedrich C Luft; Dontscho Kerjaschki; Jens Titze Journal: Nat Med Date: 2009-05-03 Impact factor: 53.440
Authors: Augustine Rajakumar; Ana Sofia Cerdeira; Sarosh Rana; Zsuzsanna Zsengeller; Lia Edmunds; Arun Jeyabalan; Carl A Hubel; Isaac E Stillman; Samir M Parikh; S Ananth Karumanchi Journal: Hypertension Date: 2012-01-03 Impact factor: 10.190
Authors: Young S Oh; Lawrence J Appel; Zorina S Galis; David A Hafler; Jiang He; Amanda L Hernandez; Bina Joe; S Ananth Karumanchi; Christine Maric-Bilkan; David Mattson; Nehal N Mehta; Gwendolyn Randolph; Michael Ryan; Kathryn Sandberg; Jens Titze; Eser Tolunay; Glenn M Toney; David G Harrison Journal: Hypertension Date: 2016-06-20 Impact factor: 10.190
Authors: Sun Hee Kim; Yu Jin Jung; Kyung Pyo Kang; Sik Lee; Sung Kwang Park; Ju-Hyung Lee; Nam Ho Kim; Won Kim Journal: Kidney Res Clin Pract Date: 2013-06-14
Authors: Anke Dahlmann; Kathrin Dörfelt; Florian Eicher; Peter Linz; Christoph Kopp; Irina Mössinger; Stephan Horn; Beatrix Büschges-Seraphin; Peter Wabel; Matthias Hammon; Alexander Cavallaro; Kai-Uwe Eckardt; Peter Kotanko; Nathan W Levin; Bernd Johannes; Michael Uder; Friedrich C Luft; Dominik N Müller; Jens M Titze Journal: Kidney Int Date: 2014-08-06 Impact factor: 10.612